Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.11.2018 | Case report

Antineoplastics

Drug resistance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Urbanska E, et al. Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT. Journal of Thoracic Oncology 13 (Suppl.): S946 abstr. P3.08-18, No. 10, Oct 2018. Available from: URL: http://doi.org/10.1016/j.jtho.2018.08.1769 [abstract] - Denmark Urbanska E, et al. Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT. Journal of Thoracic Oncology 13 (Suppl.): S946 abstr. P3.08-18, No. 10, Oct 2018. Available from: URL: http://​doi.​org/​10.​1016/​j.​jtho.​2018.​08.​1769 [abstract] - Denmark
Metadaten
Titel
Antineoplastics
Drug resistance: case report
Publikationsdatum
01.11.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-54312-6

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Antivirals

Case report

Dupilumab

Case report

Levodopa

Case report

Clozapine

Case report

Riociguat

Case report

Edoxaban